Assessing response in bone metastases in prostate cancer with diffusion weighted MRI

Objectives To determine whether changes in ADC of bone metastases secondary to prostate carcinoma are significantly different in responders compared with progressors on chemotherapy. Methods Twenty-six patients with known bone metastases secondary to prostate carcinoma underwent diffusion-weighted M...

Full description

Saved in:
Bibliographic Details
Published in:European radiology 2011-10, Vol.21 (10), p.2169-2177
Main Authors: Messiou, C., Collins, D. J., Giles, S., de Bono, J. S., Bianchini, D., de Souza, N. M.
Format: Article
Language:English
Subjects:
Aged
Aged, 80 and over
Biomarkers
Biomarkers - metabolism
Body Composition
Bone diseases
Bone Neoplasms - secondary
Cancer research
Cancer therapies
Carcinoma - diagnosis
Carcinoma - pathology
Chemotherapy
Diagnostic Radiology
Diffusion Magnetic Resonance Imaging - methods
Disease Progression
Humans
Image Processing, Computer-Assisted
Imaging
Internal Medicine
Interventional Radiology
Magnetic Resonance
Magnetic resonance imaging
Male
Medical research
Medicine
Medicine & Public Health
Metastasis
Middle Aged
Neoplasm Metastasis
Neuroradiology
Patients
Prospective Studies
Prostate cancer
Prostatic Neoplasms - diagnosis
Prostatic Neoplasms - pathology
Radiology
Scintigraphy
Time Factors
Tomography
Ultrasound
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Objectives To determine whether changes in ADC of bone metastases secondary to prostate carcinoma are significantly different in responders compared with progressors on chemotherapy. Methods Twenty-six patients with known bone metastases secondary to prostate carcinoma underwent diffusion-weighted MRI of the lumbar spine and pelvis at baseline and 12 weeks following chemotherapy. RECIST assessment of staging CT and PSA taken at the same time points were used to classify patients as responders, progressors or stable. ADC (from b  = 0,50,100,250,500,750 smm −2 ) and ADC slow (from b  = 100,250,500,750 smm −2 ) were calculated for up to 5 lesions per patient. Results Mean ADC/ADC slow in lesions from responders and progressors showed a significant increase. Although the majority of lesions demonstrated an ADC/ADC slow rise, some lesions in both responders and progressors demonstrated a fall in ADC beyond the limits of reproducibility. Conclusions Mean ADC is not an appropriate measure of response in bone metastases. The heterogeneity of changes in ADC is likely to be related to the composition of bone marrow with changes that have opposing effects on ADC.
ISSN:0938-7994
1432-1084
DOI:10.1007/s00330-011-2173-8